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Abstract Frailty is a geriatric syndrome of impaired
resistance to stressors due to a decline in physiologic
reserve. Frailty and cardiovascular disease (CVD) share a
common biological pathway, and CVD may accelerate the
development of frailty. Frailty is identified in 25% to 50%
of patients with CVD, depending on the frailty scale used
and the population studied. Frail patients with CVD,
especially those undergoing invasive procedures or suffer-
ing from coronary artery disease and heart failure, are
more likely to suffer adverse outcomes as compared to
their non-frail counterparts. Five-meter gait speed is a
simple and effective way of objectively measuring frailty
in patients with CVD and should be incorporated in risk
assessment.
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Introduction
The word frail originates from the French frêle, meaning
“of little resistance,” and from the Latin fragilis, meaning
“easily broken.” In medicine, frailty is a geriatric
syndrome used to define older adults with impaired
resistance to stressors due to a decline in physiologic
reserve [1]. The decline in physiologic reserve is multi-
factorial and involves a number of organ systems. Implicit
in this definition is the introduction of a stressor (illness,
surgery) followed by an injury and/or incomplete re-
covery, and ultimately a greater risk of mortality and
morbidity.
Frailty has become increasingly relevant in the field of
cardiovascular medicine for two principal reasons. First,
the patient population is aging; of the 6,160,000 Ameri-
cans discharged with a first diagnosis of cardiovascular
disease (CVD), 62% were ≥65 years of age, and of those
not surviving, 67% were ≥75 years or age [2]. Chrono-
logic age alone is insufficient to characterize the heteroge-
neous group of older adult patients, and consideration of
frailty is important to better reflect biological age. Second,
there is an emerging body of literature linking CVD and
frailty both at the mechanistic level and the epidemiologic
level [3].
The objectives of this review are to recapitulate the
mechanistic and epidemiologic links between CVD and
frailty and to provide a framework for when and how to
measure frailty in CVD patients based on current
evidence.
Mechanistic Link Between CVD and Frailty
Although the pathways leading to CVD and frailty are
complex, both have been strongly tied to chronic low-grade
inflammation (Fig. 1). Causes of this type of inflammation
include lifelong antigenic exposure, angiotensin 1R activa-
tion, obesity, insulin resistance, and redox imbalance [4], all
of which are found in greater relative amounts in patients
with CVD and patients with frailty. Circulating inflamma-
tory markers such as neutrophils, monocytes, high-
sensitivity C-reactive protein, and interleukin-6 (IL-6) are
increased in CVD and frailty [5–7], as are downstream
thrombotic markers such as factor VIII and D-Dimers [8].
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of lipoproteins and activation of plaques [9]. In frailty,
inflammation promotes a catabolic neurohormonal state that
serves to redistribute amino acids from skeletal muscle to
other organ systems, leading to profound loss of muscle
mass [10, 11]. Because muscle is the main reservoir for
amino acids, loss of muscle mass and change in muscle
metabolism impairs the body’s ability to maintain and
repair itself in the face of stressors [12, 13]. Hence, loss of
muscle mass is a core component of frailty.
Another common pathway leading to CVD and frailty is
insulin resistance [14, 15]. Independent of its contribution
to chronic inflammation, insulin resistance leads to im-
paired muscle protein breakdown, which in turn leads to
reduced availability of amino acids for maintenance and
repair functions. Vitamin D deficiency has also been
implicated in both CVD and frailty [16–19], as well as a
number of nuclear factors including telomere shortening
[20–23] and lamin A/C reduction [24].
In addition to sharing causal pathways, CVD has been
shown to contribute to the development of frailty [25, 26].
The mechanism remains to be elucidated, but may be
related to chronic repetitive injury and neurohormonal
activation imposed by the CVD (eg, ischemic heart disease,
hypertension, valvular heart disease).
Epidemiologic Link Between CVD and Frailty
Four studies suggested a cross-sectional association be-
tween prevalent frailty and prevalent CVD in community-
dwelling older adults: Zutphen Elderly Men’s Study (odds
ratio [OR] 4.1; 95% CI, 1.8–9.3; n=450) [27], Cardiovas-
cular Health Study (OR 2.79; 95% CI, 2.12–3.67; n=4,735)
[28], Beaver Dam Eye Study (OR 1.43 per point; 95% CI,
1.13–1.82; n=2962) [29], and the Women’s Health and
Aging Studies (OR 2.72; 95% CI, 1.72–4.30; n=670) [30].
In the Cardiovascular Health Study, there was also an
association between frailty and subclinical cardiovascular
abnormalities such as left ventricular hypertrophy and
carotid intima-media thickness.
The Women’s Health Initiative Observational Study
showed that community-dwelling older women with CVD
and cardiovascular risk factors were at higher risk of
developing incident frailty [31]. Coronary artery disease
and stroke were associated with the highest risk of
developing incident frailty (OR 1.47; 95% CI, 1.25–1.73
and OR 1.71; 95% CI, 1.24–2.36, respectively; n=40,657).
In this study and others, frailty was strongly predictive of
survival over a long-term follow-up period.
The French 3 City Study and the Health ABC Study
showed that community-dwelling older adults who were
frail (as determined by gait speed) were at higher risk of
developing incident CVD events and mortality [25, 26]. In
the French 3 City Study, slow gait speed was associated
with a threefold increase in cardiovascular mortality over
5 years (OR 3.00; 95% CI, 1.65–5.57; n=3208) but no
difference in death due to cancer or death due to other
causes, implying a specific effect of frailty on CVD.
Outside of the community setting, there have been fewer
studies examining the prevalence and prognostic impact of
frailty in hospitalized older adults or those with established
severe CVD. Purser et al. [32￿] showed that, depending on the
definition used, 27% to 50% of elderly patients admitted to a
cardiology ward with severe coronary artery disease were frail
[32￿]. Slow gait speed outperformed other markers of frailty
and was associated with a fourfold increase in mortality over
6 months (OR 4.00; 95% CI, 1.10–13.80; n=309). Cacciatore
et al. [33] showed that 54% of elderly patients with chronic
heart failure were frail, which was in turn associated with an
increase in mortality over 12 years (OR 1.62; 95% CI, 1.08–
2.45; n=1332) [33]. Using a different definition of frailty,
Boxer et al. [34] showed that 25% of elderly patients with
chronic heart failure were frail. Tjam et al. [35] showed that
frailty was more predictive of mortality than New Y ork Heart
Association (NYHA) class.
The sum of these epidemiologic studies underscores the
frequent coexistence of frailty and CVD, with the preva-
lence of frailty varying between 25% and 50% depending
on the definition used. Furthermore, these studies brought
forth the non-negligible impact of frailty on CVD events
and mortality.
When to Measure Frailty
Because frailty is a syndrome of impaired resistance to
stressors, it is well suited to predict the elderly patient’s
Fig. 1 Mechanistic link between frailty and cardiovascular disease
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ing clinical applications lies in using frailty to predict the
elderly patient’s risk of mortality and morbidity in the
setting of invasive cardiovascular procedures. In particular,
cardiac surgery imposes marked physiologic stress on
numerous organ systems, and existing risk prediction
models perform poorly in the elderly [36]. These models
contain up to 77 variables encompassing patient age, sex,
illness severity, and comorbid conditions, but they have yet
to formally incorporate an objective measure of frailty.
In the Frailty Assessment Before Cardiac Surgery
(Frailty ABC’S) Study, 46% of elderly patients aged
70 years or older undergoing coronary artery bypass
surgery and/or valve surgery were found to be frail as
measured by a 5-m gait speed ≥6s[ 37￿]. Gait speed was
not correlated with age, left ventricular ejection fraction, or
risk scores, suggesting that it was representing a distinct
domain. After adjusting for the Society of Thoracic
Surgeons (STS) risk score, slow gait speed was associated
with a threefold increase in postoperative mortality or major
morbidity (OR 3.05; 95% CI, 1.23–7.54; n=131). Slow gait
speed was also associated with greater need for discharge to
convalescence or rehabilitation facilities, and a trend toward
a longer length of stay. The value of adding gait speed to
the STS risk score was incremental and resulted in a
substantial improvement in area under the receiver operat-
ing characteristic (ROC) curve from 0.70 to 0.74 and
integrated discrimination index of 5%, two measures of
model performance.
In a study from the Maritime Heart Center Cardiac
Surgery Registry, only 4% of patients undergoing cardiac
surgery were found to be frail; having increased mortality
and discharge to convalescence or rehabilitation facilities
[38]. The low prevalence of frailty could be explained by
the mixture of elderly and non-elderly patients, and the
definition of frailty that was based on disability (“end-
stage” frailty) and dementia rather than conventional
criteria for frailty. This study underscores the relatively
lower yield of frailty in non-elderly patients and when
disability-based criteria are used.
A study from the Heart Center Leipzig included patients
aged ≥74 years undergoing cardiac surgery [39]. The
definition of frailty was based on a composite score (range
of 1–35) using a modified Cardiovascular Health Study
scale, instrumental activities of daily living, balance testing,
a panel of laboratory tests, and pulmonary function tests.
The unadjusted risk of postoperative mortality was greater
in those with higher composite scores.
Another promising clinical application for frailty lies in
predicting the elderly patient’s risk of mortality and
morbidity in the setting of heart failure [33–35]. These
patients often have very advanced age, many comorbid
conditions, frequent hospitalizations, and high mortality
rates, rendering the clinical evaluation and management
decisions complex. Frailty may enlighten the global
assessment and at times explain nonspecific symptoms
such as exhaustion and weakness.
Finally, frailty may be measured in any elderly patient
with CVD when a global assessment is desired to better
reflect complexities related to advanced age, comorbidity,
disability, and nonspecific symptomatology.
How to Measure Frailty
A number of different clinical instruments exist to objec-
tively measure the phenotype of frailty [40￿, 41]. These
instruments vary from 1 to 70 items, but tend to share
similar core items: slowness, weakness, and physical
inactivity.
One of the most widely used instruments is the
Cardiovascular Health Study (CHS) scale [42￿]. The
CHS scale includes 5 items: slowness measured by 5-m
gait speed, weakness measured by handgrip strength,
physical inactivity measured by questionnaire, exhaustion
measured by questionnaire, and unintentional weight loss
>10 lbs over 1 year measured by self-report. Three or
more positive items are required to classify the patient as
frail, and one or two positive items are required to classify
the patient as pre-frail. The pre-frail category is dis-
regarded by some because its prognostic utility is less
well established.
There have been a number of modifications to the CHS
scale. The expanded CHS scale adds two items to the
standard CHS scale—cognitive impairment and mood
disturbance—because some believe these to be integral
components of frailty. The MacArthur Study of Successful
Aging (MSSA) scale adds five items: cognitive impairment,
self-reported weakness, anorexia, high IL-6, and high CRP;
four or more positive items are required to classify the
patient as frail [43￿]. An analysis of the MSSA scale sub-
dimensions revealed that the combination of slowness,
weakness, physical inactivity, and cognitive impairment
was most predictive.
Of note, many investigators have found that the single
item of slow gait speed is most predictive of frailty and
adverse outcomes, often outperforming more elaborate
scales and other physical performance tests such as
handgrip strength, chair-rises, and balance testing [32￿, 44,
45]. The single measure of gait speed for frailty has been
endorsed by a recent task force [40￿], and has the advantage
of being easily applicable without much time or cost and
without relying on subjective questionnaires. Gait speed is
typically measured over a 5-m distance (range of 2.4–10 m,
with the distance used having little effect on measured
speed) [46] at the patient’s comfortable walking pace.
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found in Fig. 2.
Jones et al. [47] have proposed two additional frailty
scales. The Canadian Health and Aging (CHSA) Frailty
Index includes a checklist of 70 items, integrating a large
number of comorbid conditions, disabilities, cognitive
impairments, mood disturbances, and mobility limitations.
The CHSA Clinical Frailty Scale simplifies this checklist
into a semi-quantitative global judgment that classifies
patients on a scale from 1 to 7 with 1 being very fit and 7
being severely frail [48].
The Calgary Cardiac and Cognition scale was developed
in hospitalized patients aged ≥60 years undergoing cardiac
catheterization, with the stated goal of predicting worsening
activities of daily living (ADL) and quality of life over a
period of 1 year [49]. Like the CHS scale, the Calgary
Cardiac and Cognition scale includes five items with three
or more required to classify a patient as frail: cognitive
impairment measured by the Trail-Making Test Part B,
mood disturbance measured by the geriatric depression
scale, tandem balance <10 s, body mass index <21 or
>30 kg/m
2, and living alone. Gait speed was not predictive
in this study, although a short 2.4-m test was used and the
investigators pointed out that many patients were restrained
by intravenous lines. Conversely, in the Frailty ABC’S
Study, the presence of intravenous lines, walkers, and canes
did not affect the reliability of the gait speed test.
One common pitfall is equating frailty with disabilities
in ADL (e.g., getting dressed unassisted) or instrumental
ADL (e.g., going shopping unassisted). Frailty occurs
earlier and can be elicited in a large number of well-
functioning older adults; disability occurs later and can
be viewed as the end-result of longstanding frailty and
comorbidity burden. Despite the overlap between frailty,
disability, and comorbid conditions, these represent
distinct domains that are not interchangeable [50].
Another common pitfall is identifying frailty based on a
visual “eyeball” impression, especially when this visual
impression is driven by the presence of very advanced age
and low body mass index. In fact, frail patients are more
likely to have high body mass index and excess central
adiposity [14, 37￿, 51].
Future Directions
With the emergence of evidence showing the prognostic
value of frailty in elderly patients with CVD, ongoing
efforts are being directed toward incorporating frailty
into existing and novel risk prediction models. Until
these models are available, clinicians may consider
measuring frailty in selected patients on a case-by-case
basis.
Therapeutic strategies may be divided as those that
prevent or reverse the development of frailty, and those that
prevent adverse outcomes in frail patients. Interventions
likely to be beneficial in preventing frailty include regular
physical exercise [52–58] and balanced nutrition. The value
of pharmacotherapy remains to be confirmed. Interventions
likely to prevent adverse outcomes in patients found to be
frail include comprehensive geriatric assessment to opti-
mize comorbid conditions and promote early recognition of
complications such as delirium [59–61], physical therapy
[62, 63], and accessibility to social support systems [64,
65]. Moreover, frail patients requiring coronary revascular-
ization or valve replacement may benefit from less invasive
Fig. 2 Instructions for the 5-m
gait speed test
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transcatheter interventions, although this has yet to be
formally studied.
Conclusions
Frailty and CVD share common biological pathways, and
CVD may accelerate the development of frailty. Frailty is
identifiedin25%to50%ofpatientswithCVD,dependingon
thefrailtyscaleusedandthepopulationstudied.Frailpatients
with CVD, especially those undergoing invasive procedures
orsufferingfromcoronaryarterydiseaseandheartfailure,are
more likely to suffer adverse outcomes compared to their
non-frail counterparts. The 5-m gait speed test is a simple and
effective way of objectively measuring frailty in patients with
CVD and should be incorporated in risk assessment. Further
research willclarifyhowto best incorporate frailtyinexisting
risk models and how to optimize health status and prevent
adverse outcomes in frail patients.
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